ALENDRONATE FOR TREATMENT OF CHILDHOOD/ADOLESCENT GLUCOCORTICOID-ASSOCIATED OSTE

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This trial will test the hypothesis that among children and adolescents with Crohn's disease, ulcerative colitis, systemic-onset juvenile rheumatiod arthritis and juvenile dermatomyositis, treatment of glucocorticiod-associated osteopenia and osteoporosis with 18 months of alendronate (FOSAMAX, Merck & Co., Inc.) will result in greater improvement in mean changes in individual AP spine BMD (gm/cm) determined by dual energy X-ray absorptiometry (DXA) than treatment with 18 months of standard care therapy.